ABOUT US
ABOUT US
Company Profile
Management Team
Investors
Scientific Advisor
Contact Us
Company profile

Our Vision: To Translate Novel Modality into Reality


DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases. Leveraging on the decades of learning, we have successfully established a number of next-generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights.

 

These include DITAC (Duality Immune Toxin Antibody Conjugate) with significantly improved therapeutic window and DIMAC (Duality Immune Modulating Antibody Conjugate) with superior efficacy than traditional biologics. Built upon our deep understanding of disease biology and translational capability, we have built a robust pipeline of more than 10 best-in-class and/or first-in-class ADC programs with the potential to make a life changing difference for patients. Additionally, we are continuing evolving our protein engineering and ADC technology for the next wave of “super ADC” molecules including diverse payload class, bispecific ADC and dual payload ADC to further harness the potential of ADC modality. For detailed information, please see Our Approach and Pipeline.

 

The company was founded in January 2020 by Dr. John Zhu, a seasoned company builder in the healthcare industry and led by an experienced management team with proven track record in discovering and developing novel medicines for global market. We are currently operating in both China and United States.





DUALITY BIO
Scroll
Management team
John Zhu, PhD, MBA
John Zhu, PhD, MBA
Founder & CEO
  • Over 20 years of leadership role in venture investment and biotech entrepreneurship 

  • Former Partner of 6 Dimensions Capital and Wuxi Ventures. Invested/incubated many leading biotechs including CStone, Gan&Lee Pharma, BGI, Remegen, etc 

  • PhD, University of Massachusetts Medical Center; MBA, University of California, Berkeley


Yang Qiu, PhD
Yang Qiu, PhD
CSO & US GM
  • Over 20 years of MNC drug discovery and development experience with demonstrated success of leading drug discovery, translational medicine and early clinical development programs. Contributed to the discovery and progression into clinic of over 15 drug candidates and drug approvals including the most recent FDA BTD Patritumab Deruxtecan (HER3-DXd)

  • Previously as Co-chair of cross-ADC program, Senior Director of Translational Medicine at Daiichi Sankyo; Director, Head of Translational and Biomarker Research at Janssen; Director, Head of Molecular Discovery Research at GSK China

  • Postdoc in Human Genomics at Lawrence Berkeley National Lab, PhD in Molecular Biology from University of Texas at Austin, and BS from University of Science and Technology in China


Vivian Gu, MD
Vivian Gu, MD
CMO
  • 20 years of experience in managing both Global and China trials and 12 years in oncology area with experience of managing or oversight 200+ studies

  • Served as Head of Clinical Research in MNC companies like BI, AZ, BMS, Head of clinical development at Haihe and NVT holding company with experience of building the clinical development team from scratch to full functions with 200+staffs

  • Rich drug development experience in different TAs, including Cardiology, COPD, Diabetes, and oncology etc., experience of successful registration of ARB, DDP4/SGLT2, EGFR TKI, PD-1, and cell therapy etc

  • 8 years physician experience in tertiary care hospital and overseas physician experience in Singapore

Tim Xin Wang, CFA
Tim Xin Wang, CFA
Strategy and Business Development, Senior Vice President
  • 20 years of experience in Wall Street healthcare research and banking, all based in New York. Worked as a member of a top-ranked pharmaceutical equity research team at J.P. Morgan and UBS

  • Has advised many leading Asian pharmaceutical and healthcare companies on business strategy and cross-border transactions during almost 15-year stint at Mizuho Bank. Previously worked as a research scientist at Schering-Plough Corporation in New Jersey

  • Graduated top of his class from NYU Stern School of Business with four merit awards. M.Sc. degree in Biochemistry from The University of British Columbia and B.Sc. in Microbiology from Nankai University


Haiqing Hua, PhD
Haiqing Hua, PhD
Head of Drug Discovery, Vice President

  • Rich experience in the field of drug discovery and development in both multi-national company and domestic pharma company; Primary inventor of multiple novel peptide, antibody and ADC molecules; Direct contribution to IND/NDA approval of biopharmaceuticals in US or China

  • Previously as Head of Biopharmaceuticals and Competitive Intelligence at Hansoh Pharma, leading preclinical discovery and development (nonclinical and CMC), and regulatory affairs of peptide, antibody and ADC programs. Previously as Principal Investigator at Eli Lilly, leading drug screening platform, GPCR agonist/antagonist and antibody discovery programs

  • Postdoc in stem cell and gene therapy at Columbia University Medical Center (New York), PhD in neurodegenerative diseases from University of Zurich (Switzerland), and BS from Tsinghua University in China


Xin Yu, MS, PMP®
Xin Yu, MS, PMP®
Head of Regulatory Affairs, Vice President
  • Seasoned biotechnology professional with 18+ years’ experience in pharma industry

  • Multiple career experience in Agency, MNC, CRO and Biotech

  • Sound records in novel drug development. Familiar with ICH guidelines, US, China and Asia-Pacific countries regulations

  • Certified Project Management Professional (PMP®), excellent coordination in cross-functional teams and fast-paced projects

  • Received Master degree in Pharmaceutical Administration and Bachelor degree in Pharmaceutical Engineering from Shenyang Pharmaceutical University

Rong Shi, PhD
Rong Shi, PhD
Development Science, Vice President
  • Over 12 years of experience in global clinical research. Expert in optimizing drug development via leveraging knowledge between bench and bedside in oncology and immunology, from discovery, translational medicine to clinical development

  • Previously Director of Quantitative Clinical Pharmacology at Daiichi-Sankyo, led cross functional team (clinical pharmacology, pharmacometrics, bioanalytical science, DMPK, and toxicology) to support the most recent FDA BTD Patritumab Deruxtecan; Clinical Pharmacology Lead at Genentech/Roche, and Bristol Myers Squibb to support the development of more than 15 assets in early & late phase, post marketing development, and the global approval of anti-CD79b ADC Polivy

  • PhD in Pharmaceutics from University of Florida; postdoctoral fellowship at CDER FDA


Raymond Zhao,M.M
Raymond Zhao,M.M
Clinical Operation, Vice President
  • Over 16 years of experience in global and regional clinical trials with more than 10 years of experience in oncology area

  • Served as Head of Clinical Development at Fosun Kite, built clinical operation team,  led the clinical team and developed the first cell-therapy product in China

  • Served as Head of Clinical Development at Innovent, led the clinical team and developed the first PD-1 product of China

  • Master's degree in Clinical Medicine from Shanghai Tongji University


Rick Chu, PhD
Rick Chu, PhD
Translational Medicine, Vice President
  • With over 20 years of experience in the global pharmaceutical industry and a proven track record of success in leading antibody drug discovery, biomarker/clinical bioanalysis, and translational medicine programs

  • Successfully led and advanced the development of Sanofi's Isatuximab CDx, a pivotal diagnostic tool that effectively gauges patient responses to Isatuximab treatment in cases of multiple myeloma

  • Postdoc in Molecular Biology at Peking University and Molecular Pathology at Northwestern University. Ph.D. research at the Shanghai Institute of Biochemistry, CAS, the first to establish the baculovirus expression system in China






Investors
Lilly Asia Ventures
礼来亚洲基金

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, we have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, we manage over $4.5 billion of committed capital.

 

LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory knowhow, and market insights. We also have strong global perspective and connections, driven by the consolidated experience of our team members overseas as well as our network of scientific advisors. By combining our China expertise and global perspectives, we are uniquely positioned to support our portfolio companies and investors worldwide.

 

Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.


Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, we have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, we manage over $4.5 billion of committed capital.

 

LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory knowhow, and market insights. We also have strong global perspective and connections, driven by the consolidated experience of our team members overseas as well as our network of scientific advisors. By combining our China expertise and global perspectives, we are uniquely positioned to support our portfolio companies and investors worldwide.

 

Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.


King Star Capital
苏州民投翼朴资本

King Star Capital, founded in 2017, is the US dollar investor of Yipu capital and focuses on investing in innovative biomedical enterprises. Its core management team has been deeply engaged in private equity investment. It has nearly 20 years of experience in investment of science and technology enterprises and in promoting industrial development. 

King Star Capital

King Star Capital, founded in 2017, is the US dollar investor of Yipu capital and focuses on investing in innovative biomedical enterprises. Its core management team has been deeply engaged in private equity investment. It has nearly 20 years of experience in investment of science and technology enterprises and in promoting industrial development. 

WuXi Biologics
药明生物

WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

 

With over 10,000 skilled employees in China, the United States, Germany, Ireland and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of the end of 2021, WuXi Biologics is supporting over 480 integrated client projects, including nine in commercial manufacturing.

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.


WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide.

 

With over 10,000 skilled employees in China, the United States, Germany, Ireland and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of the end of 2021, WuXi Biologics is supporting over 480 integrated client projects, including nine in commercial manufacturing.

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.


6 Dimensions Capital
通和毓承

6 Dimensions Capital was established in 2017 by a team of prominent and experienced professionals to create a leading global investment firm with a focus on innovative life science companies in China and the United States.

20+ investment professionals and 10+ supporting staff located in Boston, San Francisco, Hong Kong and Shanghai. Fully leverages industrial resources.
Currently 6 Dimensions Capital manages 7 Funds with total assets under management over 10B RMB ($1.5B USD) and invested in and cultivated a portfolio of 80 companies to quickly advance their growth and development.

6 Dimensions Capital

6 Dimensions Capital was established in 2017 by a team of prominent and experienced professionals to create a leading global investment firm with a focus on innovative life science companies in China and the United States.

20+ investment professionals and 10+ supporting staff located in Boston, San Francisco, Hong Kong and Shanghai. Fully leverages industrial resources.
Currently 6 Dimensions Capital manages 7 Funds with total assets under management over 10B RMB ($1.5B USD) and invested in and cultivated a portfolio of 80 companies to quickly advance their growth and development.

Yunion Healthcare Ventures
楹联健康基金

Yunion Healthcare Ventures are established in early 2019, and the cornerstone investors are from the leading pharmaceutical enterprises in the industry. Guided by research, the fund deeply explores investment opportunities in cutting-edge innovative drugs, medical technologies and devices around the world, and incubates many companies with top scientists, PI and clinical transformation teams to achieve 0-1 innovation breakthroughs.

Yunion Healthcare Ventures

Yunion Healthcare Ventures are established in early 2019, and the cornerstone investors are from the leading pharmaceutical enterprises in the industry. Guided by research, the fund deeply explores investment opportunities in cutting-edge innovative drugs, medical technologies and devices around the world, and incubates many companies with top scientists, PI and clinical transformation teams to achieve 0-1 innovation breakthroughs.

Hua Gai Capital
华盖资本

Founded in 2012, Hua Gai Capital has a professional management team from well-known investment companies in the industry arund the world. With the vision of "becoming the most trusted capital partner for entrepreneurs and investors", Hua Gai Capital focuses on private equity investment in the three fields: health care, TMT and digital innovation, and is committed to promoting the growth of small and medium-sized enterprises into industry leaders. At present, 's Hua Gai Capital's assets under management are about 20 billion in RMB.

Hua Gai Capital

Founded in 2012, Hua Gai Capital has a professional management team from well-known investment companies in the industry arund the world. With the vision of "becoming the most trusted capital partner for entrepreneurs and investors", Hua Gai Capital focuses on private equity investment in the three fields: health care, TMT and digital innovation, and is committed to promoting the growth of small and medium-sized enterprises into industry leaders. At present, 's Hua Gai Capital's assets under management are about 20 billion in RMB.

Oriza Holdings
元禾控股

Suzhou Oriza Holdings Corporation is an investment holding company in charge of over 100 billion in RMB. Its business covers equity investment, credit finance and equity investment services, including China's first Equity Investment Fund of Funds, the first science and finance market .

In twenty years, Oriza Holdings, motivated by the mission and vision of “Leading in the equity investment, practicing in creation of science and technology, and creating continuous value”, builds an integrated system of investment and financing business. Assisted by professional investment service system, Oriza Holdings has achieved a great success in exploring financial creation, boosting science creation, guiding fund accumulation and upgrading industries through the coordination of the three businesses of capital operation, risk control and operation allocation.

Since 2001, Oriza Holdings has been committed to the equity investment area. There are different subordinate focuses on different investment period and area. By the end of Mar. 2021, 960 deals invested by the direct investment platform; The VC FoFs invested in 123 portfolio funds, total size of the portfolio funds is over RMB150 billion, with over 2500 portfolio companies invested; 153portfolio companies on the equity investment have already succeeded in IPO.

In 2010, Oriza Holdings, together with the CDB Capital Company, established the largest RMB Fund of Funds-Guochuang Fund of Funds, of which the VC Fund of Funds (Guochuang Oriza Holdings Venture Capital Fund) is managed by Oriza Holdings. It was used to invest the early and long-term venture capital funds.

In 2017,Sandlake Fund Town,which is the only town relevant to financial industry,has been successfully listed one of the first batch of 25 provincial featured towns. By the end of Mar. 2021, Sandlake Fund Town has gathered 410 equity investment funds, a total of 2436 billion Yuan, 7 credit financing services and over 4500 investment enterprises.

Oriza Holdings, committed to the corporate culture of aggressiveness and creation, offers an overall help to the enterprises that lack of capital. It is the first option for the enterprises. What’s more, it tries to become a world-leading investment holding company!


Oriza Holdings

Suzhou Oriza Holdings Corporation is an investment holding company in charge of over 100 billion in RMB. Its business covers equity investment, credit finance and equity investment services, including China's first Equity Investment Fund of Funds, the first science and finance market .

In twenty years, Oriza Holdings, motivated by the mission and vision of “Leading in the equity investment, practicing in creation of science and technology, and creating continuous value”, builds an integrated system of investment and financing business. Assisted by professional investment service system, Oriza Holdings has achieved a great success in exploring financial creation, boosting science creation, guiding fund accumulation and upgrading industries through the coordination of the three businesses of capital operation, risk control and operation allocation.

Since 2001, Oriza Holdings has been committed to the equity investment area. There are different subordinate focuses on different investment period and area. By the end of Mar. 2021, 960 deals invested by the direct investment platform; The VC FoFs invested in 123 portfolio funds, total size of the portfolio funds is over RMB150 billion, with over 2500 portfolio companies invested; 153portfolio companies on the equity investment have already succeeded in IPO.

In 2010, Oriza Holdings, together with the CDB Capital Company, established the largest RMB Fund of Funds-Guochuang Fund of Funds, of which the VC Fund of Funds (Guochuang Oriza Holdings Venture Capital Fund) is managed by Oriza Holdings. It was used to invest the early and long-term venture capital funds.

In 2017,Sandlake Fund Town,which is the only town relevant to financial industry,has been successfully listed one of the first batch of 25 provincial featured towns. By the end of Mar. 2021, Sandlake Fund Town has gathered 410 equity investment funds, a total of 2436 billion Yuan, 7 credit financing services and over 4500 investment enterprises.

Oriza Holdings, committed to the corporate culture of aggressiveness and creation, offers an overall help to the enterprises that lack of capital. It is the first option for the enterprises. What’s more, it tries to become a world-leading investment holding company!


Green Pine Capital Partners
松和资本

Founded in 1996, Green Pine Capital Partners  was  initiated by venture investors Li Wei and Luo Fei and is a local venture capital companies with a long history in China. The core team has more than 20 years of experience in technology investment. Green Pine capital partners' portfolio covers many high-tech fields such as digital economy, new materials and bio-medicine. It always focuses on companies which have innovative technology and pay attention to the construction of technology platform. It searches the future stars through professional ability and assists the growth of the enterprise through capital operation experience. At present, the asset under management Green Pine capital partners exceeds 16 billion in RMB, and nearly 400 projects have been invested, half of which are in early stage. 55 projects exited through IPO or merger and acquisition by listed companies. At the same time,  Green Pine capital partners adhering to the ESG investment concept, takes the social responsibility to donate funds to schools, protect multi-ethnic cultural and environment.

Green Pine Capital Partners

Founded in 1996, Green Pine Capital Partners  was  initiated by venture investors Li Wei and Luo Fei and is a local venture capital companies with a long history in China. The core team has more than 20 years of experience in technology investment. Green Pine capital partners' portfolio covers many high-tech fields such as digital economy, new materials and bio-medicine. It always focuses on companies which have innovative technology and pay attention to the construction of technology platform. It searches the future stars through professional ability and assists the growth of the enterprise through capital operation experience. At present, the asset under management Green Pine capital partners exceeds 16 billion in RMB, and nearly 400 projects have been invested, half of which are in early stage. 55 projects exited through IPO or merger and acquisition by listed companies. At the same time,  Green Pine capital partners adhering to the ESG investment concept, takes the social responsibility to donate funds to schools, protect multi-ethnic cultural and environment.

Scientific advisor
Dr. Antoine Yver
Chairman of Scientific Advisory Board & External Professional Director
Dr. Antoine Yver serves as Chairman of Development
Dr. Antoine Yver

Dr. Antoine Yver serves as Chairman of Development at Centessa Pharmaceuticals, Ltd. and also as an independent Director of the Board at Sanofi. Previously, Dr. Antoine Yver served as Executive Vice President, President and Global Head of Oncology R&D, and Chair of the Cancer Enterprise at Daiichi Sankyo, where his strategic leadership transformed Daiichi Sankyo from a small-molecule metabolic and cardiovascular drugmaker to an oncology biologics company.  

Dr. Yver was the vision leader for Daiichi Sankyo’s global development of oncology pipeline and his leadership was fundamental for the practice-changing success of ENHERTU®. Prior to Daiichi, he was Senior Vice President at AstraZeneca, where he led the development of the global oncology pipeline and successfully launched 11 different drug products including TAGRISSO® and LYNPARZA®. In addition, he held various clinical development roles at Johnson & Johnson, Schering-Plough, Aventis Group and Rhone-Poulenc Rorer. 

Dr. Antoine Yver has more than 25 years of oncology development and clinical experience. Dr. Yver is a pediatric oncologist and holds an M.D. from Université Paris-Saclay. He obtained a Master's degree in Immunology from the University of Paris. He completed his medical training at the Hôpitaux de Paris (AIHP).


Dr. Pasi A. Jänne
Member of Scientific Advisory Board
Dr. Pasi Jänne is a world renowned translational t
Dr. Pasi A. Jänne

Dr. Pasi Jänne is a world renowned  translational  thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science. 

Dr. Jänne’s research combines laboratory based  study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer. He has made seminal therapeutic discovery including co-discovery of EGFR mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer. 

Dr. Jänne’s translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC. Dr. Jänne has received multiple awards for his work including from the AACR,ESMO and ASCO.

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001.


Contact us
Shanghai
Address: U1104-1106, Building A, 868 Yinghua Road, Shanghai
Zip Code: 201204
Company Name:
Name:
Title:
Contact Information:
Requests Type:
please Choose
Strategy Cooperation
Media Related
Career Related
Others
Feedback Content:
Verification Code